Disease severity during SARS-COV-2 reinfection: a nationwide study

J Infect. 2022 Apr;84(4):542-550. doi: 10.1016/j.jinf.2022.01.012. Epub 2022 Jan 25.

Abstract

Objective: We aimed to look at the burden of disease caused by SARS-COV-2 reinfections and identified potential risk factors for disease severity.

Methods: We used national surveillance data to collect information on all SARS-CoV-2 primary infection and suspected reinfection cases between January 2020 until early May 2021. Reinfection cases were positive COVID-19 PCR or antigen test, 90 days after their first COVID-19 positive test. We collected information on case demographics, hospital and ICU admission, immunisation status and if individuals were at risk of complication for COVID-19.

Results: Deaths reported within 28 days of testing positive were 61% (95% confidence interval: 56% to 65%) lower in suspected COVID-19 reinfection than primary infection cases. In the unvaccinated cohort, reinfections were associated with 49% (37% to 58%) lower odds of hospital admission in cases aged 50 to 65 years in the population not identified at risk of complication for COVID-19, and 34% (17% to 48%) in those at risk. ICU admission at reinfection compared to primary infection decreased 76% (55% to 87%). Individuals at risk and those aged below 50 years, who received at least 1 dose of vaccine against COVID-19, were 62% (39% to 74%) and 58% (24% to 77%) less likely to get admitted to hospital at reinfection, respectively.

Conclusion: Prior SARS-CoV-2 infection was associated with lower odds of dying, and both prior infection and immunisation showed a protective effect against severe disease in selected populations. Older age, sex and underlying comorbidities appeared as principal risk factors for illness severity at reinfection.

Funding: PHE/UKHSA.

Keywords: COVID-19; Disease severity; Immunisation; Primary infection; Reinfection; SARS-CoV-2.

MeSH terms

  • COVID-19 Vaccines
  • COVID-19* / epidemiology
  • Humans
  • Reinfection / epidemiology
  • SARS-CoV-2*
  • Severity of Illness Index

Substances

  • COVID-19 Vaccines